Lyell Immunopharma, Inc.
LYELHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The $310.8M market capitalization puts LYEL squarely in small-cap range for its industry. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorec.
Market Cap
$310.8M
Beta
-0.06
P/E (TTM)
—
P/E (Fwd)
-15.86
EPS (TTM)
$-13.04
EPS (Fwd)
$-0.84
ROE
-80.8%
ROA
-29.9%
Cash
$254.0M
Total Debt
$48.9M
Free CF
-$77.4M
52W Change
44.2%
Annual Financials
Cash vs Debt
With $254.0M in cash and $48.9M in debt, LYEL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$77.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -80.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $84.7M (2022) to $36K (2025), a 100% decline worth watching.
The relatively low beta of -0.06 suggests LYEL is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, LYEL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing LYEL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.